These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30382485)

  • 21. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
    Schmalbrock LK; Dolnik A; Cocciardi S; Sträng E; Theis F; Jahn N; Panina E; Blätte TJ; Herzig J; Skambraks S; Rücker FG; Gaidzik VI; Paschka P; Fiedler W; Salih HR; Wulf G; Schroeder T; Lübbert M; Schlenk RF; Thol F; Heuser M; Larson RA; Ganser A; Stunnenberg HG; Minucci S; Stone RM; Bloomfield CD; Döhner H; Döhner K; Bullinger L
    Blood; 2021 Jun; 137(22):3093-3104. PubMed ID: 33598693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
    Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
    Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with
    Bewersdorf JP; Patel KK; Shallis RM; Podoltsev NA; Kewan T; Stempel J; Mendez L; Stahl M; Stein EM; Huntington SF; Goshua G; Zeidan AM
    Leuk Lymphoma; 2024 Aug; 65(8):1136-1144. PubMed ID: 38648559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
    Ramsingh G; Westervelt P; McBride A; Stockerl-Goldstein K; Vij R; Fiala M; Uy G; Cashen A; Dipersio JF; Abboud CN
    Int J Hematol; 2014 Mar; 99(3):272-8. PubMed ID: 24488798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.
    Sierra J; Montesinos P; Thomas X; Griskevicius L; Cluzeau T; Caillot D; Legrand O; Minotti C; Luppi M; Farkas F; Bengoudifa BR; Gilotti G; Hodzic S; Rambaldi A; Venditti A
    Blood Adv; 2023 Nov; 7(21):6441-6450. PubMed ID: 37581981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
    Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
    J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
    Wiesen MHJ; Stemler J; Fietz C; Joisten C; Cornely OA; Verougstraete N; Streichert T; Müller C
    Eur J Haematol; 2024 Jun; 112(6):879-888. PubMed ID: 38297484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
    Döhner H; Weber D; Krzykalla J; Fiedler W; Wulf G; Salih H; Lübbert M; Kühn MWM; Schroeder T; Salwender H; Götze K; Westermann J; Fransecky L; Mayer K; Hertenstein B; Ringhoffer M; Tischler HJ; Machherndl-Spandl S; Schrade A; Paschka P; Gaidzik VI; Theis F; Thol F; Heuser M; Schlenk RF; Bullinger L; Saadati M; Benner A; Larson R; Stone R; Döhner K; Ganser A
    Blood Adv; 2022 Sep; 6(18):5345-5355. PubMed ID: 35486475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
    Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
    Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy.
    Cairoli R; Furneri G; Di Virgilio R; Veggia B; Ferrara F
    BMC Health Serv Res; 2023 Jan; 23(1):36. PubMed ID: 36642712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.
    Berger T; Rozovski U; Moshe Y; Yaari S; Frisch A; Hellmann I; Apel A; Aviram A; Koren-Michowitz M; Yeshurun M; Ram R; Raanani P; Ofran Y; Wolach O
    Ann Hematol; 2019 Dec; 98(12):2711-2717. PubMed ID: 31512015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
    Stone RM; Manley PW; Larson RA; Capdeville R
    Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
    Andrews C; Maze D; Murphy T; Sibai H
    Br J Haematol; 2020 Aug; 190(3):467-470. PubMed ID: 32567045
    [No Abstract]   [Full Text] [Related]  

  • 38. Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
    Röllig C; Schliemann C; Ruhnke L; Fransecky L; Heydrich BN; Hanoun M; Noppeney R; Schäfer-Eckart K; Wendelin K; Mikesch JH; Middeke JM; Reimann M; Fiebig F; Zukunft S; Wermke M; Serve H; Platzbecker U; Müller-Tidow C; Baldus CD; Bornhäuser M
    Br J Haematol; 2024 Jun; 204(6):2254-2258. PubMed ID: 38593353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
    J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism.
    Morell A; Novotná E; Milan J; Danielisová P; Büküm N; Wsól V
    Arch Toxicol; 2021 Jan; 95(1):67-78. PubMed ID: 33025066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.